Introduction: A Childhood Question Becomes a Scientific Mission
For most, a cancer diagnosis in the family is a source of profound grief. For Jennifer Guerriero, PhD, that grief became the catalyst for a lifelong scientific pursuit. Her grandmother was diagnosed with breast cancer the very year Dr. Guerriero was born, and throughout her childhood, she witnessed the arduous reality of cancer treatment.
"I just remember thinking as a child, why can’t she take a pill? Why can’t she take Tylenol and her breast cancer go away?" Dr. Guerriero recalls. That deceptively simple, childlike question evolved into a sophisticated professional mission. Today, as an assistant professor at Brigham and Women’s Hospital in Boston, Dr. Guerriero is moving beyond standard treatments to explore how we can fundamentally alter the environment surrounding a tumor, effectively stripping away the defenses that keep cancer protected from the immune system.
With the recent support of the Cancer Research Institute (CRI) and the prestigious Lloyd J. Old STAR (Scientists Taking Risks) award, Dr. Guerriero is transitioning from theoretical research to the development of a pioneering, first-in-class therapy that could rewrite the rules of modern oncology.
The Chronology of a Vision
Dr. Guerriero’s path to the forefront of cancer research was not linear; it was built on years of rigorous observation and a persistent desire to solve the "resistance" problem in immunology.
- Early Foundations: Driven by her grandmother’s experience, Dr. Guerriero dedicated her academic career to understanding the cellular mechanisms of breast cancer. She identified early on that the primary failure of many treatments wasn’t the absence of immune cells, but the presence of barriers.
- The Discovery Phase: While studying the tumor microenvironment, her laboratory identified a specific group of immune cells known as tumor-associated macrophages (TAMs). These cells, which express a molecule called TREM2, were found to be pervasive in solid tumors but largely absent in healthy tissue.
- The Conceptual Leap: Recognizing that these TREM2-positive macrophages were acting as "gatekeepers" for the tumor, Dr. Guerriero conceived of an engineering approach: using monocytes to specifically target and dismantle these protective macrophages.
- Proof of Concept: Through preliminary studies in mouse models, her team successfully demonstrated that removing these suppressive macrophages allowed T cells to infiltrate the tumor, leading to tumor shrinkage and improved survival rates.
- The STAR Award: In 2026, the CRI recognized the high-risk, high-reward nature of this research, granting Dr. Guerriero the Lloyd J. Old STAR award, providing the financial runway to move her research toward clinical-grade applications.
Supporting Data: Why Current Immunotherapies Fail
Immunotherapy has undeniably revolutionized cancer care. By "releasing the brakes" on the immune system, treatments like checkpoint inhibitors have allowed T cells to recognize and destroy malignant cells. However, clinical data consistently shows that a significant percentage of patients—particularly those with solid tumors—do not respond to these therapies.
The "Why" lies in the tumor microenvironment. A tumor is not merely a collection of cancer cells; it is a complex, protected fortress. Dr. Guerriero’s research focuses on the "security guards" of this fortress: the tumor-associated macrophages (TAMs).
The Role of TREM2-Positive Macrophages
Macrophages are generally tasked with maintaining homeostasis and cleaning up cellular debris. However, in the context of a tumor, they are often "reprogrammed" by the cancer to serve its needs. These macrophages secrete factors that suppress the immune system, physically blocking T cells from reaching the cancer cells.
Dr. Guerriero’s team has confirmed that TREM2-positive macrophages are the primary culprits in this suppression. Because they are highly specific to the tumor environment, they represent an ideal target for intervention. If you can eliminate the gatekeepers, the body’s own T cells can finally reach their targets.
The Engineering Breakthrough: CAR-Monocytes
Dr. Guerriero’s proposed solution utilizes the logic of CAR-T cell therapy but shifts the objective. While standard CAR-T therapies engineer T cells to attack the tumor directly, Dr. Guerriero is engineering monocytes.
How the Process Works:
- Extraction: Monocytes (a type of white blood cell) are collected from the patient.
- Reprogramming: The monocytes are engineered with a Chimeric Antigen Receptor (CAR) specifically designed to identify and bind to the TREM2 molecule.
- Deployment: Once introduced back into the patient, these CAR-monocytes migrate to the tumor site.
- Elimination: Upon finding a TREM2-positive macrophage, the CAR-monocyte triggers its destruction.
- Immune Awakening: With the suppressive macrophages gone, the physical and chemical barrier around the tumor collapses. The patient’s endogenous T cells, previously held at bay, can now infiltrate the tumor and execute a potent anti-cancer response.
Official Responses and the "STAR" Philosophy
The Lloyd J. Old STAR award is not a typical research grant. It is designed specifically for "Scientists Taking Risks." In the world of high-stakes academic medicine, researchers often face a "funding paradox": they cannot secure funding for unproven, novel ideas, but they cannot prove those ideas without significant funding.
Dr. Guerriero is candid about this struggle. "I don’t think I could get it funded through traditional mechanisms because this is really a first-in-class, brand-new therapy," she stated.
The CRI’s decision to support her work represents a strategic pivot in how medical research is funded. By investing in the scientist rather than just the project, the CRI allows researchers the agility to hire specialized staff, procure advanced biological materials, and foster cross-institutional collaborations. For Dr. Guerriero, this means the freedom to fail, to iterate, and to push the boundaries of what is medically possible.
"It is absolutely critical that foundations and incredible institutes like CRI can step up to fund these projects that may have the potential to lead to the next breakthrough for immunotherapy," she noted.
Implications for the Future of Oncology
The potential impact of Dr. Guerriero’s work extends far beyond breast cancer. Because the suppression mechanism—the recruitment of TREM2-positive macrophages—is common across many different types of solid tumors, this therapy could eventually be adapted as a "universal" approach to tumor microenvironment modification.
A Paradigm Shift
If successful, this therapy would change the standard of care in three distinct ways:
- Synergistic Efficacy: It could be used in tandem with existing checkpoint inhibitors, potentially turning "non-responders" into patients who experience durable remissions.
- Precision Engineering: By targeting only the suppressive cells, it may reduce the systemic toxicity often associated with broad-spectrum cancer treatments.
- Broad Application: The research could potentially be applied to pancreatic, lung, and colon cancers, where the dense tumor stroma has historically prevented immunotherapy from gaining a foothold.
Conclusion: The Motivation Remains Personal
Dr. Guerriero’s laboratory is currently working toward the development of a clinical-grade product that meets the rigorous safety and efficacy standards required for human trials. While the road ahead is filled with the typical complexities of biotechnology development, the motivation behind the work remains grounded in that initial, childhood encounter with her grandmother’s illness.
"I think investing in early- to mid-stage scientists and physicians is critical," Dr. Guerriero says. "It’s going to keep the field moving forward. It’s going to help launch the next breakthrough."
By daring to look at the environment around the cancer rather than just the cancer itself, Dr. Guerriero is not just conducting research; she is building a bridge between the limitations of current medical science and the future of patient care. In doing so, she is honoring the memory of her grandmother—and perhaps, one day, she will provide the answer to that simple, poignant question she asked as a child. She may not be creating a simple pill, but she is engineering a profound solution that could make the word "incurable" a relic of the past.
